Cumberland Pharmaceuticals Launches Reditrex® Product Line For Active Rheumatoid, Juvenile Idiopathic And Severe Psoriatic Arthritis

Oct 20, 2021 at 02:48 pm by Staff

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today the national launch of its RediTrex® (methotrexate) line of pre-filled syringes designed for the safe and simple treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis.

An FDA-approved injectable methotrexate (MTX), RediTrex is designed for easy handling and dosing accuracy, resulting in increased efficacy, greater continuation rates among patients and less discomfort. RediTrex treats patients with severe, active rheumatoid arthritis and polyarticular juvenile idiopathic arthritis who have difficulty tolerating or responding to orally delivered MTX. It is also approved for symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy.

"RediTrex is available in eight dosages and is designed for subcutaneous injection," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. "The pre-filled syringes assure accurate and safe dosing and have an automatic retractable, extra-thin 29-gauge needle to reduce pain and the risk of needle sticks. They also have a large grip and concave plunger that allows patients with limited dexterity to self-administer the injection at a controlled speed. RediTrex provides these benefits while being less expensive than autoinjectors."

With more than 54 million Americans living with some form of arthritis, the disease is among the most common causes of work disability in the U.S., according to the CDC. The oral form of MTX is typically the first line of treatment for rheumatoid arthritis. As the disease progresses, the dose must be increased to stay effective, often causing intolerable gastrointestinal side effects. Injectable MTX, like RediTrex, has been proven to be more effective than oral MTX, with fewer gastrointestinal side effects. Because of the increased efficacy and tolerability, injectable MTX can delay the need to move to costly biologics, lowering overall patient treatment costs. Once disease progression requires the use of biologics, continuing the treatment of injectable MTX along with the biologic has been shown to increase overall efficacy.

Other injectable MTX options available may not optimally meet the needs of an arthritis patient. Patients are offered either a vial and syringe for self-injection, or the use of an expensive autoinjector. The vial and syringe method can be difficult for a patient to handle due to limited dexterity in their hands. Additionally, obtaining the exact dose needed while preventing skin exposure to the caustic MTX can be quite challenging for patients. The autoinjectors provide a better alternative to the vial and syringe, but they remove injection control from the patient and can be painful to administer. They are also the most expensive MTX delivery.

For more information about RediTrex, including full prescribing and safety data, visit

Sections: Grand Rounds